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Abstract
Background: Serum procalcitonin (PCT) is considered useful in predicting the likeliness of developing
bacterial infections in emergency setting. In this study, we describe PCT levels overtime and their
relationship with bacterial infection in chronic obstructive pulmonary disease (COPD) critically ill patients
with pneumonia.
Methods: We conducted a prospective cohort study in an ICU of a University Hospital. All consecutive
COPD patients admitted for pneumonia between September 2005 and September 2006 were included.
Respiratory samples were tested for the presence of bacteria and viruses. Procalcitonin was sequentially
assessed and patients classified according to the probability of the presence of a bacterial infection.
Results: Thirty four patients were included. The PCT levels were assessed in 32/34 patients, median
values were: 0.493 g/L [IQR, 0.131 to 1.471] at the time of admission, 0.724 g/L [IQR, 0.167 to 2.646]
at six hours, and 0.557 g/L [IQR, 0.123 to 3.4] at 24 hours. The highest PCT (PCTmax) levels were less
than 0.1 g/L in 3/32 (9%) patients and greater than 0.25 g/L in 22/32 (69%) patients, suggesting low and
high probability of bacterial infection, respectively. Fifteen bacteria and five viruses were detected in 15/
34 (44%) patients. Bacteria were not detected in patients with PCTmax levels < 0.1 g/L. In contrast,
bacteria were detected in 4/7 (57%) patients estimated unlikely to have a bacterial infection by PCT levels
(PCTmax > 0.1 and < 0.25 g/L).
Conclusion: Based on these results we suggest that a PCT level cut off > 0.1 g/L may be more
appropriate than 0.25 g/L (previously proposed for non severe lower respiratory tract infection) to
predict the probability of a bacterial infection in severe COPD patients with pneumonia. Further studies
testing procalcitonin-based antibiotic strategies are needed in COPD patients with severe pneumonia.
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Severe pneumonia is a common cause of acute exacerba-
tions of chronic obstructive pulmonary disease
(AECOPD) [1]. In this setting, a prompt initiation of anti-
biotics is recommended [2,3]. However, bacterial etiology
is only found in approximately 50% of cases [1,4]. Other
pathogens, such as respiratory viruses, have been reported
in severe AECOPD requiring ventilation [5,6] and pneu-
monic AECOPD [1]. Moreover, in clinical practice, signs
and symptoms of bacterial and viral lower respiratory
tract infections widely overlap [7].
Procalcitonin (PCT) has been described as a marker of
bacterial infection [8] and thus may help physicians to
limit inadequate use of antibiotics [9-11]. We previously
investigated the use of PCT in patients with AECOPD,
without pneumonia, hospitalized in the ICU [12]. In this
study, we assessed PCT levels overtime and their relation-
ship with bacterial infection in chronic obstructive pul-
monary disease (COPD) patients admitted to the ICU
with severe pneumonia. In addition, we examined
whether PCT thresholds predicting probability of bacte-
rial infection previously reported [9-11] could be efficient
in this specific population.
Methods
Patients
We conducted a monocentric prospective cohort study.
All consecutive COPD patients with suspected lower res-
piratory tract infection admitted to the medical intensive
care unit of the University Hospital of Caen between Sep-
tember 2005 and September 2006 were assessed for eligi-
bility. Only those with infiltrates present on initial chest
radiographs at admission to ICU and suspected for acute
community-acquired pneumonia were included.
Definition
We defined COPD according to the Global Initiative for
Chronic Obstructive Lung Disease Guidelines (GOLD)
2005 http://www.goldcopd.com. Pneumonic AECOPD
was defined as a new infiltrate on chest radiograph with
features of lower respiratory tract infection in COPD
patients [1,11,12]. We used the pneumonia severity index
(PSI) to estimate severity [13]. A systematic search for bac-
teria with standard methods and for viruses with sensitive
methods (i.e., PCR and RT-PCR methods), as reported
elsewhere [6,12,14-16] were performed. Briefly, sputum
or tracheal aspirates were bacteriologically processed if
less than 1% of the observed field contained squamous
epithelial cells and more than 25 neutrophils were
observed [17]. Pneumonia was considered bacteriologi-
cally confirmed when at least one of the following criteria
were present: pathogen concentration greater than 105
cfu/mL in tracheobronchial aspirations or sputum sam-
ples; blood culture positive for a bacterial pathogen in the
absence of an extrapulmonary focus [17-19]. In addition,
a serological diagnostic for antibodies to Legionella pneu-
mophila was performed by indirect immunofluorescence,
associated with a detection of Legionella pneumophila
serogroup 1 antigen in urine samples in all patients.
Study design
The ethical board decided approval was not necessary
given the observational nature of the study. Accordingly,
no informed consent was obtained from the patients. At
baseline, COPD severity, according to GOLD criteria,
other comorbidities, and clinical and biological variables
were recorded [12]. All patients were treated according to
the recommendations of the French Consensus Confer-
ence [3] (i.e., an antibiotic treatment is recommended in
severe pneumonia and severe exacerbation of COPD
patients requiring admission in ICU).
Measurement of serum procalcitonin
Procalcitonin (PCT) assessment followed standard meth-
ods described elsewhere [12]. The circulating levels of PCT
were sequentially assessed at ICU admission (PCT-H0),
after six hours (PCT-H6), and after twenty fours (PCT-
H24) hours in ICU. All blood samples were analyzed at
the end of the study period. PCT was measured using a
sensitive immunoassay (Kryptor PCT, Brahms, Hen-
nigsdorf, Germany) with a functional assay sensitivity of
0.06 g/L, about fourfold above mean normal levels [20].
Patients were classified into three groups based on proba-
bility of bacterial infection according to the highest pro-
calcitonin level measured (PCTmax). As previously
reported [9-11], the groups were: group 1, PCTmax < 0.1
g/L indicating an a low probability of a bacterial infec-
tion; group 2, PCTmax > 0.1 and < 0.25 g/L indicating an
unlikely or possible bacterial infection infection; and
group 3, PCTmax > 0.25 g/L indicating a high probabil-
ity of bacterial infection.
Statistical analysis
Quantitative and qualitative data were expressed as means
(+/- SD), or median (interquartile range, IQR) and per-
centage (with their 95% confidence intervals (CI) based
on normal approximation), respectively. Categorical vari-
ables were compared using the chi-square or Fischer's
exact test, as appropriate. Quantitative variables were
compared using the Student t-test or the Mann-Whitney
non parametric test, as appropriate. The level of signifi-
cance was set at 0.05 and all tests were two-sided. We used
EPI-INFO version 6.04 dfr (EPI-INFO, CDC, Atlanta, GA)
for data collection, and EPI-INFO and SAS version 9.1
(SAS Institute Inc, Cary, NC) for data analysis.Page 2 of 7
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Patients and baseline characteristics
During the study period, 80 COPD patients with sus-
pected lower respiratory tract infection were admitted to
the ICU, 34 had pneumonia. Baseline characteristics of
the pneumonic AECOPD patients are shown in Table 1.
Twenty three patients (68%) had severe or very severe
COPD. During the previous 30-day period, antibiotic or
oral steroid therapy for exacerbations of COPD was
reported by 7 and 8 patients, respectively. Eleven patients
had received antibiotics within the 24 hours preceding
ICU admission. With the exception of 4 patients, all had a









Age, yr 70 ± 10 71 ± 10 71 ± 10 69 ± 10
Male sex, no.(%) 28(82) 2(66) 6(86) 18(82)
SAPS II score 37 [20-50] 27 [23-30] 31 [24-44] 40 [34-62]
LOD score 6 [4-10] 6 [4-10] 6 [411] 6 [4-10]
Comorbidities, no (%)
Current smokers, 11(32) 0 4(57) 7(32)
Chronic alcohol abuse 8(24) 2(66) 1(14) 4(18)
Obesity 12(35) 3(100) 2(29) 5(23)
Coronary artery disease 14(41) 1(33) 3(43) 9(41)
Hypertensive heart disease 17(50) 1(33) 2(29) 12(55)
Congestive heart disease 9(26) 1(33) 0 8(36)
Diabetes mellitus 13(38) 0 3(43) 8(36)
Chronic pseudomonas colonisation, no (%) 4(12) 0 2(29) 2(9)
Antibiotics in 24 H prior ICU admission¶, no (%) 11(32) 0 2(29) 8(36)
During the previous 30-day period¶¶
Antibiotics for AECOPD 7(20) 0 2(29) 5(23)
Oral steroid therapy for AECOPD 8(24) 1(33) 3(43) 5(23)
Severity of COPD, no (%)
GOLD stage I (mild) 2(6) 0 0 2(9)
GOLD stage II (moderate) 9(26) 1(33) 0 6(27)
GOLD stage III (sever) 3(9) 0 0 3(14)
GOLD stage IV (very sever) 20(59) 2(66) 7(100) 11(50)
Home oxygen, no (%) 18(53) 2(66) 5(71) 11(50)
Home non-invasive ventilation, no (%) 6(18) 1(33) 2(28) 3(14)
Oral or inhaled steroid, no (%) 19(56) 2(66) 6(85) 10(45)
Examination at ICU admission, no (%)
Dyspnea 34(100) 3(100) 7(100) 22(100)
Cough 11(32) 1(33) 3(43) 7(32)
Sputum 16(47) 2(66) 3(43) 11(50)
Rales 15(44) 1(33) 1(14) 12(55)
Wheezing 16(47) 2(66) 6(86) 7(32)
Body temperature, °C 37.3 ± 1.2 37.0 ± 0.7 36.5 ± 0.7 37.7 ± 1.3
Leucocytes count (×109/L) 13.7 ± 6.4 11.2 ± 0.4 12.5 ± 3.4 14.9 ± 7.4
Pneumonia severity index (PSI)
PSI I, II, III 4(11) 1(33) 2(28) 1(5)
PSI IV 14(42) 1(33) 4(57) 8(36)
PSI V 16(47) 1(33) 1(14) 13(59)
Values are given as No.(%), median [25%-75% interquartile range], or mean ± standard deviation
* Levels of procalcitonin (PCT) were assessed in 32/34 patients. PCT is given in g/L
¶ One patient receiving antibiotic in 24 h prior ICU was not assessed for PCT levels
¶¶ Patients treated with antibiotic or oral steroid during the previous 30-day period for exacerbation of COPD were exclusive of those receiving 
antibiotic in 24 h prior ICUPage 3 of 7
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required ventilator support: non invasive ventilation
(NIV) in 23 (68%) patients and invasive mechanical ven-
tilation in 20 (58%) patients, 9 of whom received invasive
mechanical ventilation after NIV failure. All patients
received antibiotics and inhaled steroids and 18 (53%)
systemic steroids. The mean length of ICU stay was 29 ±
31 days. The mean length of non-invasive ventilation,
invasive mechanical ventilation, and ventilation-free days
during the ICU stay were 2.85 ± 5.1 days, 17.8 ± 31.1 days,
and 2.56 ± 2.34 days, respectively. Fourteen patients
developed septic shock, nine during the first hours follow-
ing ICU admission and five during their ICU stay. Six
patients developed ventilator-associated pneumonia.
Twenty two patients were discharged from the hospital.
Twelve patients died, eight from septic shock, three from
COPD-related respiratory failure, and one from malig-
nant bronchospasm complicated with cardiac arrest.
PCT measurements and clinical correlates
The median [25%-75% IQR] PCT levels were as follows:
at admission PCT-H0 was 0.493 g/L [0.131-1.471], PCT-
H6 was 0.724 g/L [0.167-2.646], and PCT-H24 was
0.557 g/L [0.123-3.4].
PCT levels were not different in patients who had received
antibiotics within the month or 24 hours prior to ICU
admission, compared to antibiotic-naive patients (PCT-
H0 0.695 g/L [0.202-1.139] vs 0.470 g/L [0.088-1.471],
p = 0.73 and PCT-H0 0.942 g/L [0.202-22.110] vs 0.438
g/L [0.088-0.902], p = 0.22, respectively). In addition,
steroids prior to ICU admission did not influence PCT lev-
els (p = 0.76). PCT-H0 was significantly higher when
abnormal breath sounds or rales were present (PCT-H0
1.661 g/L [0.745-26.83] vs 0.207 g/L [0.086-0.470], p =
0.0005) and when fever > 38°C was present; PCT-H0
1.495 g/L [0.828-56.48] vs 0.272 g/L [0.087-0.902], p =
0.0.05). No association was found between PCT-H0 levels
and the presence or absence of sputum and cough.
The PCTmax was < 0.1 g/L in 3/32 patients (9%),
between 0.1 and 0.25 g/L in 7/32 patients (22%), and >
0.25 g/L in 22/32 patients (69%), including 20 patients
with PCTmax > 0.5 g/L. There were no associations
between PCTmax levels > 0.25 g/L and severity of COPD
(p = 0.21), Simplified Acute Physiology Score type II (SAP-
SII) (p = 0.15), Logistic Organ Dysfonction (LOD) (p =
0.29), and PSI (p = 0.08).
PCTmax levels and bacterial findings
Figure 1 depicts bacterial findings according to PCTmax
levels. The dynamics of PCT measurements and bacterial
findings are shown Figure 2. Fifteen (44%) patients had
microbiologically-confirmed pneumonia. Fifteen bacteria
(4 Pseudomonas aeruginosa, 3 Haemophilus influenzae, 3
Streptoccocus species, 3 Methicillin-resistant Staphyloccocus
aureus, 1 Serratia species, and 1 Fusibacterium nucleatum)
and 5 viruses (3 rhinovirus, 1 human metapneumovirus,
and 1 respiratory syncitial virus) were detected. A co-infec-
tion was detected in 3 cases (rhinovirus and Streptoccocus,
rhinovirus and Haemophilus influenzae, and rhinovirus
and Fusibacterium nucleatum). Seven patients cross over
between PCT groups over time (Figure 2). No bacteria
were detected in patients with PCTmax level < 0.1 g/L. In
contrast, bacteria were detected in more than half the
patients estimated to have an unlikely bacterial infection
(PCTmax > 0.1 and < 0.25 g/L).
Discussion
Our study examined microbiological findings and PCT
levels in critically ill COPD patients admitted for pneu-
monia. To our knowledge, this has not been addressed in
the specific setting of the ICU. In agreement with previous
report [11], PCT level < 0.1 g/L could indicate a low
probability of bacterial infection in approximately 10% of
patients (3/32). In contrast, bacteria were detected in
more than half the patients (4/7) with PCT levels suggest-
ing an unlikely or possible bacterial infection (PCTmax
between 0.1 and 0.25 g/L), as previously defined outside
the ICU [9-11]. Therefore, a PCT cut off below 0.25 g/L
for antibiotic use may not be appropriate for severe pneu-
monia patients with COPD admitted to the ICU.
We found a median PCT level of 0.493 g/L [0.131-1.471]
in COPD patients admitted to the ICU for pneumonia,
this finding is consistent with previous studies focusing
on community-acquired pneumonia (CAP) [11,21].
However, in these two large prospective cohorts focusing
on CAP, less than 25% of patients had COPD and less
than 10% were admitted to the ICU. In previous reports,
PCT levels were not different between patients pre-treated
with antibiotics and antibiotic-naive patients [10,11], a
finding confirmed by our study. In contrast to previous
reports, we found an association between PCT levels and
clinical symptoms (fever and abnormal breath sounds or
rales).
The distribution of patients according to PCTmax levels
(ie < 0.1 g/L, 0.1 to 0.25 g/L, and > 0.25 g/L) was sim-
ilar to that previously reported by Christ-Crain et al [11].
In patients (10%) with PCTmax levels < 0.1 g/L, bacteria
were not detected, suggesting antibiotics may be unneces-
sary in this subgroup. In contrast, bacteria were detected
in more than half the patients with PCT levels suggesting
an unlikely or possible bacterial infection (PCTmax > 0.1
and < 0.25 g/L). This result suggests a PCT level cut-off >
0.1 g/L, rather than > 0.25 g/L (proposed for non severe
pneumonia [11]), may be more appropriate for initiating
antibiotics in a PCT based antibiotic strategy in criticallyPage 4 of 7
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ever, remains to be conducted.
In addition, this study confirms the importance of a
sequential PCT levels assessment to predict probability of
bacterial infection specifically when the first measure-
ment is low (i.e., PCT < 0.1 g/L). Indeed, three from five
patients crossing over from PCT group < 0.1 g/L to PCT
group 0.1-0.25 g/L over time, had bacteriologically doc-
umented pneumonia. This point should have important
implications for furthers studies assessing procalcitonin-
based antibiotic strategies in this setting.
We are aware of the limitations of our study, which
include the monocentric design and small sample size. In
addition, a prior ICU admission antibiotic treatment in a
subset of patients may have affected the results of micro-
biological examinations. However, all patients pre-treated
with antibiotics had PCT levels higher than 0.25 g/L
(except two in PCT group 0.1-0.25 g/L) indicating a high
probability of the presence of bacterial infection.
Strengths of the study include the dynamic measurement
of PCT along with the systematic search for bacteria in a
specific population. For this reason, we believe this study
adds useful information about PCT levels in COPD
patients with severe pneumonia requiring admission to
ICU and the likelihood of bacterial infection.
Conclusion
This study reports that less than 10% of COPD patients
suspected of severe pneumonia had PCT levels lower than
0.1 g/L suggesting a low probability of a bacterial infec-
tion and that a subset of patient with PCT levels between
0.1 and 0.25 g/L (range previously reported as indicating
an unlikely or possible bacterial infection [9-11]) had a
documented bacterial infection. Based on these results we
hypothesize that a PCT level cut off > 0.1 g/L may be
more appropriate than 0.25 (previously proposed for non
severe lower respiratory tract infection [9-11] to predict
the probability of a bacterial infection in severe COPD
Distribution of the highest procalcitonin level measurements (PCTmax) and microorganism findings in chronic obstructive pul-monary disease (COPD) patients with pn umoniFigure 1
Distribution of the highest procalcitonin level measurements (PCTmax) and microorganism findings in 
chronic obstructive pulmonary disease (COPD) patients with pneumonia. Also shown is the probability of bacterial 
infection according to procalcitonin (PCT) levels, as previously reported by Christ-Crain (11). * Procalcitonin (PCT) levels 
were not assessed in 2 patients. ** One patient receiving antibiotic in 24 h prior ICU was not assessed for PCT levels.Page 5 of 7
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otic strategy. However, in clinical practice, a such procal-
citonin-based antibiotic strategy using the PCT threshold
of 0.1 g/L should have only a limited impact on the deci-
sion to initiate antibiotics in this setting. Further studies
are necessary to assess the capability of procalcitonin
guidance to shorten antibiotic duration in critically ill
COPD patients with pneumonia.
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